Cigna earnings beat by $0.04, revenue topped estimates

Cigna (NYSE: CI) reported strong second-quarter results, with EPS of $7.20 surpassing the $7.16 analyst estimate and revenue of $67.2 billion exceeding the $62.66 billion consensus. However, the company's FY 2025 EPS guidance of $29.60 was slightly below the $29.69 analyst consensus. Despite the Q2 beat and a 'great performance' financial health rating, Cigna's stock has seen a notable decline of over 10% in both the last three and twelve months, indicating investor caution despite the recent operational strength.

Analysis

Cigna (CI) reported a solid second quarter, with earnings per share of $7.20 exceeding analyst estimates by $0.04 and revenue of $67.2 billion significantly surpassing the $62.66 billion consensus. This top-and-bottom-line beat, along with an InvestingPro financial health score of "great performance", points to strong current operational execution. However, this positive performance is contrasted by a more cautious forward-looking picture. The company's full-year 2025 EPS guidance of $29.60 fell just short of the $29.69 consensus, potentially signaling future margin pressure or a conservative management outlook. This aligns with a negative trend in analyst sentiment, evidenced by 16 negative EPS revisions compared to only 6 positive revisions over the last 90 days. The market appears to be weighing these future concerns heavily, as the stock has underperformed, declining approximately 11% over the past three months and 10% over the last year, despite the strong quarterly results.

Key Decisions for Investors

• Investors should weigh the company's strong Q2 performance and favorable financial health rating against the slight miss on FY2025 guidance and negative stock momentum before initiating or adding to a position.
• The high ratio of negative to positive analyst EPS revisions (16 to 6) warrants caution, suggesting that consensus expectations may continue to trend downwards, potentially limiting near-term share price appreciation.
• Given the stock's 10% decline over the past year despite a strong revenue beat, value-oriented investors might see an opportunity, but should closely monitor future guidance and analyst commentary for signs of stabilization or further deterioration in the outlook.